Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...
Now the nation’s top health official, Kennedy is reevaluating the US Health and Human Services’s contract with Moderna, which ...
HHS review of a vaccine contract sparks worries about preparedness for a potential bird flu pandemic
HHS is re-evaluating a nearly $600 million contract with Moderna to develop and test vaccines against flu viruses that could ...
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
“The company does not expect an impact on the study's efficacy readout ... Barré risks for GSK, Pfizer RSV shots, but just one will need safety trial Moderna's president, Stephen Hoge, M.D ...
Emerging tools enable more accurate antigen production and presentation using mRNA instead of protein. In recent years, mRNA technology has come into its own, most prominently in the field of vaccine ...
Moderna, Inc. ( NASDAQ: MRNA) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET All right, well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.
According to Pfizer and BioNTech, this is the first time that an mRNA-based flu vaccine has started a phase 3 efficacy trial. Its rival Moderna said earlier this month, however, that it has ...
1 lineage of Omicron but is already being superseded by sister strain KP.3. Still, Pfizer/BioNTech and Moderna say they expect their new vaccines will retain protective efficacy as the two strains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback